Skip to main content
SpringerLink
Log in

Control of Tumor Growth Via Inhibition of Tumor Angiogenesis

  • Chapter
Book cover Gene Therapy of Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 451))

Abstract

It has been proposed for several decades that angiogenesis is an intrinsic part of tumor development and progression (1). Vice versa, inhibition of tumor angiogenesis might be a therapeutic approach to treat malignant tumors (ref. 2, for review see ref. 3). These hypotheses are based on the following observations: (i) tumor cells are able to secrete endothelial cell growth factors and to induce angiogenesis in in vivo test systems such as the chorioallantoic membrane assay (1), (ii) malignant tumors are consistently better vascularized than their benign counterparts or precursor lesions (a phenomenon which has been described as a “switch to the angiogenic state,” ref. 4), and (iii) several compounds that have been shown to inhibit endothelial cell proliferation in vitro, inhibited tumor growth in vivo (for review see ref. 5).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Folkman J, 1990; What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (82): 4–6

    Article  PubMed  CAS  Google Scholar 

  2. Gimbrone M.A, Jr., Leapman S B, Cotran R S, Folkman J, 1972; Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136: 261–276

    Article  PubMed  Google Scholar 

  3. Folkman J, Hanahan D, 1991; Expression of the angiogenic phenotype during development of murine and human cancer. In: Origins of human cancer: A comprehensive review. Cold Spring Harbor Laboratory Press, pp 803–814

    Google Scholar 

  4. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364, 1996

    Article  PubMed  CAS  Google Scholar 

  5. Moses MA, Langer R. Inhibitors of angiogenesis. Biotechnology 9: 630–634 (1991)

    Article  PubMed  CAS  Google Scholar 

  6. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S. Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhard, C., Desclerc, C., Pawling, M., Moons, L., Collen, D., Risau, W., and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435–439, 1996

    Article  PubMed  CAS  Google Scholar 

  7. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K.S., Powell-Braxton, L., Hillan, K., and Moore, M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439–442, 1996

    Article  PubMed  CAS  Google Scholar 

  8. Fong G-H, Rossant J, Gertsenstein M, Breitman ML: Role of the fit-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66–70, 1995

    Article  PubMed  CAS  Google Scholar 

  9. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in flk-1 deficient mice. Nature 376: 62–66, 1995

    Article  PubMed  CAS  Google Scholar 

  10. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Quin Y (1995) Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation. Nature 376: 70–74

    Article  PubMed  CAS  Google Scholar 

  11. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato N, Yancopoulos G. Requisite role of angiopoietin-1, a ligand for the tie2 receptor, during embryonic angiogenesis. Cell 87: 1171–1180, 1996

    Article  PubMed  CAS  Google Scholar 

  12. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich T, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis. Science 277: 55–60, 1997

    Article  PubMed  CAS  Google Scholar 

  13. Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumour angiogenesis. Brain Pathol 4: 207–218

    Article  PubMed  CAS  Google Scholar 

  14. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 15: 339–347, 1995

    Article  PubMed  CAS  Google Scholar 

  15. Breier G, Damert A, Plate KH, Risau W. Angiogenesis in embryos and ischemic diseases. Thrombosis and Haemostasis 78: 678–683 (1997)

    PubMed  CAS  Google Scholar 

  16. Plate KH. Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer & Metastasis Reviews 15: 237–240 (1996)

    Article  CAS  Google Scholar 

  17. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309, 1989

    Article  PubMed  CAS  Google Scholar 

  18. Conolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470–1478, 1989

    Article  Google Scholar 

  19. Keck PJ, Hauser S, Krivi G, Sanzo K, Warren T, Feder J, Conolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (246): 1309–1312, 1989

    Article  PubMed  CAS  Google Scholar 

  20. Alon T, Hemo I, Itin A, Peér J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Medicine (1):1024–1028, 1995

    Article  PubMed  CAS  Google Scholar 

  21. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94: 8761–8766, 1997

    Article  PubMed  CAS  Google Scholar 

  22. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845–848, 1992

    Article  PubMed  CAS  Google Scholar 

  23. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845, 1992

    Article  PubMed  CAS  Google Scholar 

  24. Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270:19761–19766, 1995

    Article  PubMed  CAS  Google Scholar 

  25. Levy, A.P., Levy, N.S., and Goldberg, M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271: 2746–2753, 1996

    Article  PubMed  CAS  Google Scholar 

  26. Damert A, Machein M, Breier G, Fujita MQ, Hanahan D, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Research 57: 3860–3864, 1997

    PubMed  CAS  Google Scholar 

  27. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams, LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989–991, 1992

    Article  PubMed  Google Scholar 

  28. Terman BC, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bšhlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Comm 187: 1579–1586, 1992

    Article  PubMed  CAS  Google Scholar 

  29. Millauer B, Wizigmann-Voos S, SchnŸrch H, Martinez R, Moller NPH, Risau W, Ullrich A: High affinity VEGF binding and developmental expression suggests flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835–846, 1993

    Article  PubMed  CAS  Google Scholar 

  30. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J Cancer 59:520–529, 1994

    Article  PubMed  CAS  Google Scholar 

  31. Kremer C, Breier G, Risau W, Plate KH. Upregulation of flk-1/VEGF receptor-2 by its ligand in a cerebral slice culture system. Cancer Research 57: 3852–3859, 1997

    PubMed  CAS  Google Scholar 

  32. Stratmann A, Machein MR, Plate KH. Anti-angiogenic gene therapy of malignant gliomas. Acta Neurochirugica, Suppl. 68:105–110, 1997

    CAS  Google Scholar 

  33. Kim JB, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844, 1993

    Article  PubMed  CAS  Google Scholar 

  34. Kondo S, Asano M, Suzuki H (1993) Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Comm 194: 1234–1241

    Article  PubMed  CAS  Google Scholar 

  35. Millauer B, Shawver L, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576–578, 1994

    Article  PubMed  CAS  Google Scholar 

  36. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM (1996) Dominant-negative inhibition of flk-1 suppresses the growth of many tumour types in vivo. Cancer Res 56: 1615–1620

    PubMed  CAS  Google Scholar 

  37. Kendall RL, Thomas KA. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705–10709, 1993

    Article  PubMed  CAS  Google Scholar 

  38. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK. Flk-1 as a target for tumour growth inhibition. Cancer Research 56: 3540–3545, 1996

    PubMed  CAS  Google Scholar 

  39. Saleh M, Stacker SA, Wilks AF (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56: 393–401

    PubMed  CAS  Google Scholar 

  40. Cheng SY, Huang HJS, Nagane M, Ji XD, Wang DG, Shih CCY, Arap W, Huang CM, Cavenee WK (1996) Suppression of glioblastoma angiogenicity and tumourigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93: 8502–8507

    Article  PubMed  CAS  Google Scholar 

  41. Claffey KP, Brown LF, Delaguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF (1996) Expression of vascular permeability factor vascular endothelial growth factor by melanoma cells increases tumour growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172–181

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurocenter, Freiburg University Medical School, 79106, Freiburg, Germany

    Dr. Karl H. Plate

  2. Abteilung Neuropathologie, Neurozentrum der Albert-Ludwigs-Universität, Breisacherstrasse 64, D-79106, Freiburg, Germany

    Dr. Karl H. Plate

Authors
  1. Dr. Karl H. Plate
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl H. Plate .

Editor information

Editors and Affiliations

  1. Humboldt University, Berlin, Germany

    Peter Walden , Uwe Trefzer , Wolfram Sterry  & Patricia Zambon , ,  & 

  2. King’s College School of Medicine and Dentistry, London, UK

    Farzin Farzaneh

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Plate, K.H. (1998). Control of Tumor Growth Via Inhibition of Tumor Angiogenesis. In: Walden, P., Trefzer, U., Sterry, W., Farzaneh, F., Zambon, P. (eds) Gene Therapy of Cancer. Advances in Experimental Medicine and Biology, vol 451. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5357-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5357-1_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7444-2

  • Online ISBN: 978-1-4615-5357-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation